Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients.

Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients / G. Baldin, A. Ciccullo, S. Rusconi, A. Capetti, G. Sterrantino, M. Colafigli, G. D'Ettorre, A. Giacometti, M.V. Cossu, A. Borghetti, W. Gennari, C. Mussini, V. Borghi, S. Di Giambenedetto. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - (2019 Sep 12). [Epub ahead of print] [10.1016/j.ijantimicag.2019.09.002]

Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients

S. Rusconi;A. Capetti;M.V. Cossu;
2019-09-12

Abstract

Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients.
ART; HIV; dolutegravir; dual therapy; lamivudine; simplification; two-drug regimen
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
Long-term data on DTG+3TC switch, IJAA 2019.pdf

embargo fino al 01/08/2019

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 817.33 kB
Formato Adobe PDF
817.33 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/677701
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 25
social impact